Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.British journal of cancer · 2026
   Review
2. Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.Annals of hematology · 2026
   Article
3. Epigenetic Targeting in Myeloid Malignancies.Advances in experimental medicine and biology · 2026
   Review
4. Innovative gene engineering strategies to address tumor antigen escape in cell therapy.Journal of translational medicine · 2025
   Review
5. Novel approaches to the use of hypomethylating agents in myeloid malignancies.Epigenomics · 2025
   Review
6. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.Advances in therapy · 2022
   Review
7. Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data.Northern clinics of Istanbul · 2022
   Article
8. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.Chinese medical journal · 2020
   Review
9. Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis.Experimental hematology & oncology · 2020
   Review
10. Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.Cancers · 2018
    Review
11. How and when to decide between epigenetic therapy and chemotherapy in patients with AML.Hematology. American Society of Hematology. Education Program · 2017
    Review
12. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Blood reviews · 2017
    Review
13. MYC-Master Regulator of the Cancer Epigenome and Transcriptome.Genes · 2017
    Review
14. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.International journal of molecular sciences · 2017
    Article
15. Future prospects of therapeutic clinical trials in acute myeloid leukemia.Future oncology (London, England) · 2017
    Review
16. Hypomethylating Agents as a Therapy for AML.Current hematologic malignancy reports · 2017
    Review
17. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.Yonsei medical journal · 2017
    Article
18. New drugs in acute myeloid leukemia.Annals of oncology : official journal of the European Society for Medical Oncology · 2016
    Review
19. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines.Clinical proteomics · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

9 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as